New Weight-Loss drug candidate enters early human testing
NCT ID NCT06945419
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests an investigational drug called LY4086940 in healthy people and those with overweight, obesity, or type 2 diabetes. The main goal is to check the drug's safety and how the body processes it. About 216 participants will receive single or multiple doses over several weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Pharmacology of Miami
Miami, Florida, 33172, United States
-
Endeavor Clinical Trials
San Antonio, Texas, 78240, United States
-
Fortrea Clinical Research Unit
Daytona Beach, Florida, 32117, United States
-
Fortrea Clinical Research Unit
Dallas, Texas, 75247, United States
-
Lilly Centre for Clinical Pharmacology
Singapore, 138623, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Personality type may influence diabetic wound healing – a study investigates
- Timing your meals or halving your rice: a new trial tests simple diet hacks for weight loss and blood sugar control
- Does injection location matter for a new Weight-Loss drug? a trial investigates
- Can a strong support network help people with diabetic kidney disease take better care of themselves?
- Can a new drug boost Semaglutide's power against diabetes and obesity?
- Can a Normal-Weight baseline improve heart risk assessment in type 1 diabetes?